Increased levels of inflammatory cytokines, including tumor necrosis factor (TNF), interleukin-1 (IL-1), and IL-6, have been detected in specimens from human immunodeficiency virus type 1 (HIV-1)-infected individuals. Here we demonstrate that HIV-1 activates the expression of TNF but not of IL-1 and IL-6 in acutely and chronically infected T cells. The increase in TNF gene expression is due to activation of the TNF promoter by the viral gene product Tat. Transactivation of TNF gene expression requires the product of the first exon of the tat gene and is cell type independent. T cells chronically infected with pol-defective HIV-1 provirus constitutively express both Tat and TNF at levels significantly higher (fivefold) than those seen in control cells, and treatment with phorbol myristate acetate greatly enhances Tat expression and TNF production. As TNF can increase the production of IL-1 and IL-6 and these inflammatory cytokines all enhance HIV-1 gene expression and affect the immune, vascular, and central nervous systems, the activation of TNF by Tat may be part of a complex pathway in which HIV-1 uses viral products and host factors to increase its own expression and infectivity and to induce disease.
Tumor necrosis factors a and ,B (TNFa and TNFP), interleukin-1 alpha (IL-la) and IL-1I, and IL-6 have been found to be elevated in the serum or produced at high levels by cultured leukocytes of human immunodeficiency virus type 1 (HIV-1)-infected individuals (9, 42, 57) . Previous studies have indicated that these inflammatory cytokines activate HIV-1 gene expression and replication, interrupting virus latency and increasing virus spread (1, 4, 30, 55) . These cytokines also modulate the immune, vascular, and central nervous systems (15, 39, 54) . These observations have suggested that these cytokines play a role in the pathogenesis of AIDS and associated diseases, such as Kaposi's sarcoma (KS), B-cell lymphomas, and neurological disorders (4, 10, 16, 34, 49) . In particular, TNF, IL-1, and, to a lesser extent, IL-6 stimulate the proliferation of spindle cells derived from KS lesions of AIDS patients (AIDS-KS cells) (4, 49) and induce KS cell phenotypic changes in normal vascular cells, the potential progenitors of the AIDS-KS cells (4) .
The increased level of inflammatory cytokines in HIV-1-infected individuals may be due, at least in part, to antigenic stimulation, which is a frequent event in most of the groups at risk for AIDS (56, 69) . In addition, HIV-1 infection itself induces the production of inflammatory cytokines from monocytes, through the binding of the envelope protein of HIV-1 (gpl20) to the CD4 molecule, and from B cells through other pathways (47, 60, 76 ). An alternative mechanism is that cytokine gene expression is transactivated by HIV-1 regulatory proteins in infected T cells. In support of this hypothesis is the observation that a B-cell line constitutively expressing the HIV-1 tat gene product (Tat) produces TNFI (67 Cell lines. The epithelial cell line COS-1, the CD4+ T-cell lines H9, Jurkat, and A301, the T-cell line 8E51, chronically infected with a pol-defective HIV-1 provirus (26) , and the promonocytic cell line U937 were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum at 37°C in a humidified atmosphere containing 5% carbon dioxide in air. AIDS-KS cells were established and cultured as previously described (16, 17, 20 Tat-expressing U937 cell line. The tat gene (40) was introduced into the retroviral vector pXT1, which is driven by the Moloney murine leukemia virus LTR and contains the neomycin resistance gene (neo). This construct was transfected into a packaging cell line and selected with G418, as described previously (8, 50) . The resulting virus was used for infection of U937 cells, which were selected again with G418.
Plasmids. The CD7-CAT plasmid, containing the HIV-1 LTR; the ABS-CAT plasmid, containing the HIV-1 LTR deleted of 4 bp at the top of the stem-loop structure (+32 to +36) of the Tat trans-activation response (TAR) sequence; the pCV-Tat plasmid and its control vector pCVO; and the pTax, pTAT, and pSVO-CAT plasmids have all been previously described (13, 17, 19, 29, 40) . The TNFP-CAT plasmids were constructed as follows. The sequence from -305 to + 115, containing the TNFP promoter region and a portion of exon I for the gene (52) , was amplified by the polymerase chain reaction technique, as described previously (64) . The primers used for the polymerase chain reaction amplification were 5'-CAGCTGCTCA ACCACCTCCT-3' (-305 to -286) and 5'-CCAAGGCCCA GGCCCAGGCA-3' (+144 to + 163).
The adaptor sequence 5'-ATTAGAAGC TT-3', cleaved by the HindIII restriction enzyme, was added to the 5' end of each primer. The amplified fragment was then digested with HindIII and cloned upstream of the chloramphenicol acetyltransferase (CAT) gene in the pSVO-CAT plasmid (29) , in both the sense (pTNFP) and antisense (pASTNFP) orientation. The nucleotide sequence and the orientation of the two constructs were confirmed by sequence analysis.
Transfection experiments and CAT assay. Transfections of the plasmid DNA were performed by the electroporation procedure, which was adapted to suspended and adherent cells. For the lymphocytic and monocytic cell lines, 3 x 107 cells were resuspended in 0.25 ml of the growth medium containing EGTA (ethylene glycol tetraacetic acid, 1 mM), transferred to Eppendorf tubes, and gently mixed with 10 jig of total plasmid DNA. After 10 min of incubation in ice, the cells were electroporated at 960 ,uF and 0.25 kV with a Bio-Rad Gene Pulser. After an additional 10 min in ice, the cells were resuspended in 25 ml of warm (37°C) growth medium and harvested 72 h later. For adherent cells, 80 to 90% confluent COS-1 cells from a 175-cm3 flask were treated with cold trypsin, washed, and gently resuspended in 1.6 ml of electroporation buffer (272 mM sucrose, 7 mM potassium phosphate [pH 7.4], 1 mM MgCl2). Eight hundred microliters of the cell suspension was mixed gently with 30 ,g of total plasmid DNA and incubated in ice for 10 min. Cells were electroporated at 25 ,uF and 0.28 kV. After an additional 10 min in ice, the cells were very gently resuspended in 25 ml of warm (37°C) growth medium and harvested 48 h later. CAT assays were performed with cell lysates (normalized for total protein content) as described previously (19, 29) . Lysates from cells transfected with the CD7-CAT plasmid were incubated for 0.5 to 1.5 h, while those from cells transfected with TNF,B-CAT plasmids were incubated for 6 h or overnight.
HIV-1 infection of H9 cell line. H9 cells (2 x 107, 106/ml) were infected with 6 x 105 cpm of reverse transcriptase from the HIV-1 IIIB isolate (17) . H9 cells (106/ml) were maintained in growth medium, and viral infection was monitored by evaluating syncytium formation, reverse transcriptase activity, and HIV-1 p24 expression. Total RNA was extracted from infected and uninfected control cells at 3-day intervals postinfection for 12 days (RNAzol; CINNA/ BIOTECX).
Northern blot analysis. Northern blot analyses were performed with 10 ,ug of total RNA, as described previously (46) . The TNFP mRNAs increased during acute HIV-1 infection (2.6-and 8.5-fold, respectively, at 9 days p.i.) compared with the amounts in uninfected control cells, whereas IL-1-and IL-6-specific transcripts were undetectable in both uninfected and HIV-1-infected cells (data not shown). These results were corroborated by the results from a radioimmunoprecipitation assay and ELISA of these cytokines in cell extracts and supernatants from infected and uninfected H9 cells (data not shown). Hybridization with the tat cDNA probe indicated that the kinetics of TNF and Tat-containing viral transcripts were temporally associated, as the levels of Tat and TNF,B transcripts peaked at 9 days p.i. (237-and 8.5-fold, respectively) ( Fig. 1A and B) . Tat-expressing cells and TNF-positive infected cells were detected by immunohistochemistry (data not shown). These results indicated that HIV-1 infection activated the expression of TNFa and TNF,B but not that of other inflammatory cytokines and suggested that Tat may be responsible for this induction.
TNF gene expression and promoter activation in Tat-expressing U937 cells. To determine whether the tat gene was able to activate TNF gene expression, a monocytic cell line (U937) which expresses no TNF constitutively was infected with a Moloney murine leukemia virus LTR-driven retrovirus vector carrying the tat gene and the neo gene, which confers resistance to the selective agent G418 (U937-Tat). The control cell line was infected with the same retrovirus vector that lacked the tat sequence (U937-CR). After 3 weeks of selection, cells were analyzed for the expression of tat and cytokine genes (Fig. 2) . The U937-Tat cell line but not the U937-CR cells expressed high levels of both Tat and TNF mRNAs (Fig. 2) , while transcripts of the other cytokines were not detectable (data not shown). As expected, HTLV-I infection, known to activate the expression of TNF and of other cytokines (32, 38, 75, 77) , resulted in higher levels of TNFI mRNA, which served as a positive TNFI control (Fig. 2) . These results confirmed previous data (67) and indicated that HIV-1 Tat was sufficient to activate TNF gene expression.
To investigate the mechanism of Tat induction of TNF gene expression, studies were performed with the TNFI gene promoter. The promoter region and part of the first exon of the TNFI3 gene (-305 to +115) (52) was cloned in both the sense (pTNF3) and antisense (pASTNF3) orientation into pSVO-CAT (29) (Fig. 3A) . TNFP promoter-CAT plasmids were transfected into U937-Tat and U937-CR cells. TNF,B-CAT expression was detected only in U937-Tat cells (Fig. 3B, right panel (8, 50) . M, size markers. specificity of Tat activity was supported by the lack of transactivation with the TAR-defective BS-CAT plasmid after transfection into U937-Tat cells (Fig. 3B , left panel; Table 1 ). After long-term culture of U937-Tat cells, Tat expression and activity were reduced, and little or no activation of the TNF, promoter was observed (data not shown). These data demonstrated that Tat activated TNF,B promoter-driven expression.
Tat-mediated activation of TNFO gene expression in cell lines of different origins. To determine whether the TNF gene activation by Tat was cell type dependent, the tat gene expressed from different promoters and the TNFO-CAT constructs were cotransfected into T-lymphocytic (Jurkat), monocytic (U937), and epithelial (COS-1) cell lines (Table 1) . Although differences in the levels of CAT activity were seen for the different cell types and with the different tat-expressing vectors, activation of the TNFI promoter by Tat was always observed (Table 1 ). These and previous data (67) had no effect on expression from the TNF, promoter (data not shown). As expected, the HTLV-I tax gene product induced the expression of TNF3, confirming that Tax is responsible for the increased level of this cytokine in HTLV-I-infected T cells (44, 75) .
In cotransfection experiments with a tax-expressing plasmid (pTax) (13), TNFI-CAT activity was comparable to that induced by Tat (Table 1) . When the TNFP-CAT plasmids were transfected into H9 cells constitutively expressing tat exon I (H9-TAT exon I) (63) , similar levels of TNFI-CAT activity were induced by the first exon of tat as in H9 cells expressing full-length tat (data not shown). This indicated that the first exon of tat is sufficient for transcriptional activation of both the TNFO and HIV-1 promoters (68) , suggesting that similar mechanisms may mediate cellular and viral gene expression by Tat.
TNFj3 gene activation in T cells chronically infected with a pol-defective HIV-1 provirus. Viral latency is one of the major features of HIV-1 infection in vivo (21, 43) and in vitro (11, 25) . At least in part, this phenomenon may be due to the presence of defective HIV-1 proviruses, which have been extensively detected in infected individuals (7, 48) . In these situations, little or no infectious viral progeny is produced. To determine whether, under these conditions, the virus alters normal cellular functions, studies were performed with T cells chronically infected with a pol-defective HIV-1 provirus (8E51 cell line) (26) . These cells do not produce infectious virus particles but do express functional Tat (Fig.  4A and 5B, and data not shown). To determine whether the level of Tat in this system was sufficient to activate the TNF, promoter, transfection experiments were performed with 8E51 cells and the parent uninfected A301 cells. Both the HIV-1 LTR and the TNFI promoter were constitutively activated (fivefold increase) in the 8E51 cell line when compared with the A301 cell line (Fig. 4A) . Similar results were obtained after cotransfection of tat and TNFI3-CAT plasmids into A301 cells (data not shown). In addition, the total content of TNF, was 5.5-fold higher in 8E51 than in A301 cells, as measured by ELISA (Fig. 4B, Table 2 ).
PMA synergizes with HIV-1 infection in increasing TNF production in chronically infected T cells. Viral latency can be interrupted by immune stimulation (31, 51, 70, 74, 78) . This is a frequent event in most of the groups at risk for AIDS (56, 69) . Activated immune cells express inflammatory cytokines (12) and, when infected with HIV-1, produce viral gene products (31, 51, 70, 74, 78) . Therefore, we investigated whether PMA could synergize with Tat in inducing TNF,B gene expression. Both the HIV-1 LTR and the TNFI promoter were transfected into 8E51 cells before and after induction with PMA. The activation of both promoters was significantly higher when the plasmids were transfected into PMA-treated 8E51 cells than into untreated 8E51 cells (5.7-and 8.9-fold increase in TNF,B-CAT and HIV-1 LTR-CAT activities, respectively). To the contrary, little or no effect was observed with PMA-treated A301 cells (1.4-and 1.6-fold increase, respectively) (data not shown). Stimulation with PMA also increased TNFO-CAT activity in H9-TAT exon I cells (7.6-fold increase) when compared with activity in untreated cells.
After PMA treatment, a dramatic increase in endogenous
TNFoi mRNA levels was observed in 8E51 cells, which peaked 8 h after stimulation (28-fold increase) and was associated with increased levels of tat-containing viral transcripts ( Fig. 5A and B, Table 2 ). Increased TNFI protein content was consistently detected in both cell extracts and supernatants of PMA-treated 8E51 cells compared with untreated cells (1.2 ng/ml at 12 h after PMA induction, representing a 41-fold increase) (Fig. SC, Table 2 ). To the contrary, TNF3-specific transcript and protein levels were low to undetectable in PMA-treated A301 cells (Fig. SA , Table 2 ). DISCUSSION Our data demonstrate that infection of T cells by HIV-1 activates the expression of TNF but not that of other inflammatory cytokines which have been found to be increased in HIV-1-infected individuals. TNF is also produced by T cells chronically infected with defective HIV-1 proviruses, and T-cell activation signals greatly increase the amount of the protein produced by the cells. Similarly, the viral transactivator Tat activates the expression of TNF but not that of IL-1 and IL-6 in transfected cells. The expression and/or activity of Tat and TNF is temporally related, as the expression of TNF and Tat increases in infected or Tattransfected cells. These results indicate that Tat is responsible, at least in part, for the TNF gene activation observed during HIV-1 infection. Tat increases the amount of TNF transcripts; this effect is mediated by the first exon of tat and is cell type independent. Tat transactivation of HIV-1 requires both LTR upstream regulatory elements and the TAR sequence, a stable mRNA stem-loop structure present in all HIV-1 transcripts (5, 23, 28, 35, 41, 53, 61 b0c.
--s- 21 6 i? 24l i. sion not only by promoting transcriptional elongation through the TAR sequence but also by facilitating the initial events in transcriptional initiation complex formation (6) . Both mechanisms may also be true for Tat-mediated TNF gene expression. The ability of Tat to transactivate a cellular gene in a TAR-RNA-independent manner proposes a complex mechanism for Tat transactivation. Consequently, TNFI3 promoter mutational analyses are being performed to map a putative functional response element for Tat transactivation.
T cells chronically infected with pol-defective HIV-1 proviruses (8E51) constitutively produce TNF, although the levels of production are variable and generally low. However, after stimulation with PMA, the amount of TNF produced in 8E51 cells consistently increases (Fig. 5C , Table  2 ). The activation of the TNF gene detected after PMA stimulation may be largely mediated by increased levels of Tat, as suggested by the increased Tat expression and activity on the HIV-1 LTR and by the similar results obtained with PMA-treated H9-TAT exon I cells. After PMA induction, parallel increases in TNF transcript and protein levels are present in the first 8 to 12 h compared with untreated cells (28-and 41-fold increase, respectively). In the following 24 h, the levels of both decline, although TNF protein content is still elevated after 48 h of stimulation compared with untreated cells (Fig. 5A and C Since TNF and other inflammatory cytokines are growth factors for AIDS-KS cells (4), we investigated whether the AIDS-KS cell growth effect of extracellular Tat (17) was mediated by induction of these cytokines. Purified recombinant Tat protein at concentrations that stimulate AIDS-KS cell growth (picograms or nanograms per milliliter) (17) did not induce or increase the production of TNF, IL-1, or IL-6 (data not shown). This observation is concordant with the higher concentration of extracellular Tat required to mediate the transactivation of HIV-1 gene expression (6, 18, 27) . Indeed, concentrations of extracellular Tat that induce cell growth do not activate the HIV-1 or TNFP promoter (18) (data not shown). To the contrary, at concentrations that cause transactivation of HIV-1 LTR-directed gene expression, extracellular Tat was also able to stimulate the expression of TNF (data not shown). These results indicated that the mechanisms for Tat transactivation of gene expression and for Tat-induced cell proliferation may be different.
Increased levels of TNF may play a role in the pathogenesis of AIDS and AIDS-associated disorders and in increasing the production of IL-1 and IL-6. TNF stimulates AIDS-KS cell proliferation and, with other cytokines, enhances the growth responsiveness of normal vascular cell types to Tat (4). These events may contribute to the development of KS in infected individuals. In vivo evidence for this role comes from studies of patients with AIDS-associated KS (1). In these individuals, treatment with recombinant TNFa leads to progression of the KS lesions and an increase in HIV-1 p24 antigenemia (1) . TNF is also a growth factor for B cells (37, 54) and thus may be involved in the pathogenesis of the AIDS-associated B-cell lymphomas. Since Tat induces TNF3 gene expression in B cells (67) and TNF is produced by B cells from HIV-1-infected individuals (60) , TNF may participate in the process of lymphomagenesis. Furthermore, TNF may play a role in the pathogenesis of AIDS-associated neurological disorders, since it has cytotoxic effects on the central nervous system (62) .
In our systems, the IL-1 and IL-6 genes are not induced by Tat. However, antigenic stimulation, HIV-1 gp120, and TNF are able to activate the expression of these cytokines (45, 47, 60, 66, 76) . This may explain the mechanisms by which IL-1 and IL-6 levels are increased in HIV-1-infected individuals. We and others have shown previously that these inflammatory cytokines are capable of inducing HIV-1 gene expression and replication in vitro and in vivo (1, 4, 30, 55) and are able to rescue Tat-defective proviruses (4). Thus, an autocrine pathway involving host factors, induced by Tat, may amplify HIV-1 gene expression and replication, interrupting viral latency and increasing virus spread, infectivity, and disease outcome. These observations lead us to consider TNFs as potential targets for AIDS therapy.
